Diagnostic delay in rare diseases: systematic review
e202201001
Keywords:
Rare diseases, Time to diagnosis, Diagnostic delay, Systematic reviewAbstract
Background: The aims of the International Consortium for Rare Diseases Research (IRDiRC) include that the diagnosis of a known rare disease (RD) must be made within a year. The objective of this systematic review was to identify the scientific evidence about the time to diagnosis in patients affected by RDs and also to know if there is a diagnostic delay (more than one year) according to the objective set by the IRDiRC.
Methods: A systematic review was carried out according to PRISMA criteria in the PubMed, Scopus and Web of Science (WoS) databases. The quality of the articles was assessed using the STROBE statement.
Results: 17 articles were included. They were devoted to specific RDs, most of them metabolic diseases, neurological and disorders that affect immunity. The study designs were mainly cross-sectional, and two retrospective cohorts were also included. Most articles showed that it takes more than a year to get a diagnosis for these RDs.
Conclusions: Scientific literature quantifying the time to diagnosis is still scarce and no study addresses RDs as a whole. In most cases, it takes more than one year to obtain a diagnosis of a RD, so there is an obvious delay according to the objective set by the IRDiRC. Therefore, new advances in the RD field are necessary to reduce the time from the onset of symptoms to the accurate diagnosis.
Downloads
References
Posada M, Alonso V, Bermejo E. Enfermedades raras. Madrid: Los libros de la catarata; 2016.
Alonso V, Villaverde-Hueso A, Hens M, Morales-Piga A, Abaitua I, Posada de la Paz M. Public health research on rare diseases. Georgian Med News. 2011;193:11-6.
Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D et al. Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin Transl Sci. 2018;11:21–27.
FEDER, Federación Española de Enfermedades Raras. Estudio ENSERio. [Consultado 26/07/2021]. Disponible en: https://enfermedades-raras.org/index.php/estudio-enserio
Dawkins H, Draghia-Akli R, Lasko P, Lau L, Jonker A, Cutillo C et al. Progress in rare diseases research 2010-2016: An IRDiRC perspective. Clin Transl Sci. 2018;11(1):11-20.
PRISMA. [Consultado 26/07/2021]. Disponible en: https://prisma-statement.org/
Orphanet [Internet]. Portal de información de enfermedades raras y medicamentos huérfanos [Consultado 26/07/2021]. Disponible en: https://www.orpha.net/
STROBE [Consultado 26/07/2021]. Disponible en: https://www.strobe-statement.org/
Dang D, Fournier P, Cariou E, Huart A, Ribes D, Cintas P et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020;7:2418-2430.
Vanherpe P, Fieuws S, D’Hont A, Bleyenheuft C, Demaerel P, De Bleecker J et al. Late- onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures. Orphanet J Rare Dis. 2020;15(1):83.
Balashova M, Tuluzanovskaya I, Glotov O, Glotov A, Barbitoff Y, Fedyakov M et al. The spectrum of pathogenic variant of the ATP7B gene in Wilson disease in the Russian Federation. J Trace Elem Med Biol. 2020;59:126420.
Tafakori-Delbari M, Cheraghi T, Yazdani R, Fekrvand S, Delavari S, Azizi G et al. Clinical manifestations, immunological characteristics and genetic analysis of patients with hyper-immunoglobulin M syndrome in Iran. Int Arch Allergy Immunol. 2019;180(1):52-63.
Kuiper GA, Meijer O, Langereis E, Wijburg F. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications. Orphanet J Rare Dis. 2018;13:2.
Zielonka M, Garbade S, Kölker S, Hoffmann G, Ries M. A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features. Genet Med. 2018;20(5):524-530.
Zielonka M, Garbade S, Kölker S, Hoffmann G, Ries M. Ultra-orphan lysosomal storage diseases: A cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis. 2019;42:975-983.
Mukhina A, Kuzumelo N, Rodina Y, Kondrokatenko I, Bologoy A, Latysheva T et al. Primary Immunodeficiencies in Russia: data from de National Registry. Front Immunol. 2020;11:1491.
Schröter J, Döring J, Garbade S, Hoffman G, Kölker S, Ries M et al. Cross-sectional quantitative analysis of the natural history of TUBA1A and TUBB2B tubulinopathies. Genet Med. 2021;23(3):516-523.
D’Amico A, Catteruccia M, Baranello G, Politano L, Govoni A, Carlo-Previtali S et al. Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. Neuromuscul Disord. 2017;27:447-451.
Devaney R, Pasalodos S, Suri M, Bush A, M Bhatt J. Ataxia telangiectasia: presentation and diagnostic delay. Arch Dis Child. 2017;102:328-330.
Högler W, Langman C, Gomes da Silva H, Fang S, Linglart A, Ozono K et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019;20:80.
Indelicato E, Nachbauer W, Eigentler A, Amprosi M, Matteucci R, Giunti P et al. Onset features and time to diagnosis in Friedreich’s Ataxia. Orphanet J Rare Dis. 2020;15:198.
Bunschoten C, Blomkwist-Markens P, Horemans A, van Doorn P, Jacobs B. Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24 (3):253-259.
Palese F, Sartori A, Logroscino G, Pisa F. Predictors of diagnostic delay in amyotrophic lateral sclerosis: cohort study based on administrative and electronic medical records data. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):176-185.
Malek A, Rashtchizadeh N, Kavandi H, Hajialilo M, Kolahi S, Nakhjavani et al. Clinical characteristics and long-term outcome of Takayasu arteritis in Iran: a multicentre study. Turk J Med Sci. 2020;50(4):713-723.
Lee J, Seiffert-Sinha K, Attwood K, Sinha A. A retrospective study of patient-reported data of bullous pemphigoid and mucous membrane pemphigoid from US-bases registry. Front Immunol. 2019;10:2219.
Prior J, Ranjbar H, Belcher J, Mackie S, Helliwell T, Liddle J et al. Diagnostic delay for giant cell arteritis- a systematic review and meta-analysis. BMC Med. 2017;15(1):120.
Lin CW, Kalb S, Yeh WS. Delay in diagnosis of spinal muscular atrophy: a systematic literature review. Pediatr Neurol. 2015;53(4):293-300.
Inaba A, Furuhata M, Morimoto K, Rahman M, Takahashi O, Hijikata M et al. Primary ciliary dyskinesia in Japan: systematic review and meta-analysis. BMC Pulm Med. 2019;19:135.
Vicente E, Casas L, Ardanaz E. Origen de los programas de cribado neonatal y sus inicios en España. Anales Sis San Navarra. 2017;40(1):131-140.
Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis. 2012;35(4):603-611.
Loeber JG, Platis D, Zetterström RH, Almashanu S, Boemer F, Bonham JR et al. Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. Int J Neonatal Screen. 2021;7(1):15.
Downloads
Published
How to Cite
License
Copyright (c) 2022 Minerva Berrocal-Acedo, Juan Benito-Lozano, Verónica Alonso-Ferreira, Ángel Vilches-Arenas
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
